Ensysce Biosciences, Inc.
Close on Oct 19, 2026
- Market cap
- $6.56M
- P/E (TTM)
- –
- Dividend yield
- –
About Ensysce Biosciences
Pharmaceutical Preparations, SIC 2834
Ensysce Biosciences, Inc. is a clinical-stage pharmaceutical company focused on developing proprietary drug platforms intended to prevent prescription drug abuse and overdose. Its technology includes Trypsin-Activated Abuse Protection (TAAP) and Multi-Programmed Abuse Resistance (MPAR), with lead opioid product candidates such as PF614 and PF614-MPAR designed for the management of severe to moderate chronic pain and the treatment of opioid use disorder. The company primarily targets patients requiring continuous analgesic therapy and healthcare markets affected by opioid misuse.
The company conducts its business within the United States, operating as a clinical-stage research and development enterprise that relies on third-party contract research and contract manufacturing organizations. Ensysce Biosciences maintains its principal executive offices in La Jolla, California.
Summary of the business section of Ensysce Biosciences's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Ensysce Biosciences, Inc.
- Founded
- 2003
- Headquarters
- La Jolla, CA
- Address
- 7946 Ivanhoe Avenue, Suite 201 92037
- Phone
- (858) 263-4196
- Employees
- 8, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- Baker Tilly US, LLP, San Diego, California
Stock & identifiers
- Ticker
- ENSC
- Exchange
- Nasdaq
- IPO date
- Dec 1, 2017
- Shares outstanding
- 19M, Aug 12, 2026
- Public float
- $5.30M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- Stock splits
- 1-for-15 reverse, Mar 10, 2025; 1-for-15 reverse, Dec 6, 2024; 1-for-12 reverse, Mar 31, 2023; 1-for-20 reverse, Oct 28, 2022; 9-for-4, Aug 16, 2021
- SEC CIK
- 1716947
- CUSIP
- 293602504
- ISIN
- US2936025046
- EIN
- 82-2755287
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| James William Morrison | President, Director | – |
| Bob G. Gower | Director | 916,740 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2024 Dr. Lynn Kirkpatrick | $442.39K | $442.39K | $357.45K | $0 | – |
| FY2023 Dr. Lynn Kirkpatrick | $508.58K | $507.19K | $417.15K | $0 | – |
| FY2022 Dr. Lynn Kirkpatrick | $622.61K | $152.79K | $573.79K | $1 | – |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Employees
Headcount reported in annual reports
“We have eight full-time employees and two part-time employees.”
Corporate history
Events identified from SEC filings